ArticleCancer biomarkers : section A of Disease markers2017
Clinical significance of circulating tumor cells in squamous cell lung cancer patients.
Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Circulating tumor cells prior to initial treatment is an important prognostic factor of survival in non-small cell lung cancer: a meta-analysis and system review.BMC pulmonary medicine · 2019Pooled it
- Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.Scientific reports · 2018Trial
- Circulating Molecular Biomarkers for the Diagnosis and Monitoring of NSCLC-A Review.International journal of molecular sciences · 2025Review
- Current and future applications of liquid biopsy in non-small-cell lung cancer-a narrative review.Translational lung cancer research · 2023Review
- ZEB1-activated Notch1 promotes circulating tumor cell migration and invasion in lung squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2023Article
- Integration of liquid biopsy and immunotherapy: opening a new era in colorectal cancer treatment.Frontiers in immunology · 2023Review
- Progress and application of circulating tumor cells in non-small cell lung cancer.Molecular therapy oncolytics · 2021Review
- Emerging Lab-on-a-Chip Approaches for Liquid Biopsy in Lung Cancer: Status in CTCs and ctDNA Research and Clinical Validation.Cancers · 2021Review
- Review
- Post-Surgery Circulating Tumor Cells andCancers · 2019Article
- The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer.Frontiers in oncology · 2018Review
- Plasma exosome levels in non-small-cell lung cancer: Correlation with clinicopathological features and prognostic implications.Cancer biomarkers : section A of Disease markers · 2018Article
- Association of epithelial-to-mesenchymal transition circulating tumor cells in non-small cell lung cancer (NSCLC) molecular subgroups.Journal of thoracic disease · 2017Article
- Molecular characterization and prognostic significance of circulating tumor cells in patients with non-small cell lung cancer.Journal of thoracic disease · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSquamous cell carcinoma (SCC) of the lung represents 20-30% of non-small cell lung cancers (NSCLC) and is associated with a poor prognosis.
objectiveThis study aims to investigate the presence of circulating tumor cells (CTCs) in squamous cell lung cancer patients and what its role might be in providing prognostic information.
methodsSerial blood samples from 100 patients both before and after initiation of one cycle of standard chemotherapy were analyzed using CellSearch system.
resultsOf 105 patients enrolled, 100 were evaluable. ≥ 2 CTCs per 7.5 mL of blood were present in 29% of patients at baseline before chemotherapy, and 9% patients have more than 5 CTCs. Based on the current literature, the CTC measurements were dichotomized as 2-4 versus ≥ 5 CTCs. In the univariate analysis, CTC count ≥ 5 at baseline and CTC count ≥ 5 at both time points (before and after one cycle of chemotherapy) were significantly associated with a poor PFS and OS outcome. Both factors remained independent poor prognostic markers in the stepwise multivariate analysis.
conclusionOur study indicate that the CTC count is a prognostic factor for PFS and OS outcomes in Chinese patients with locally advanced SCC of the lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.